339 / 400
SPONSORS AND EXHIBITORS
331
› Monday, 9 October 2017
InS-01
Industry Symposium
11:45– 13:15
|
Hall A2
Pushing back frontiers in neuropsychiatric disease
therapy
Chair:
Siegfried Kasper, Austria
Organiser:
Dr. Willmar Schwabe GmbH & Co. KG
001
Anxiety therapy: Closing the gap between
efficacy and safety
Hans-Peter Volz, Germany
002
Behavioural and psychological symptoms
associated with dementia (BPSD): Prevalence,
clinical importance and treatment options
Armin von Gunten, Switzerland
InS-02
Industry Symposium
11:45– 13:15
|
Hall New York 2
Tranylcypromin – effektives und sicheres
Management therapieresistenter Depression mit
dem Ansatzpunkt Monoaminoxidase
Chair:
Mazda Adli, Germany
Organiser:
Aristo Pharma GmbH
001
Monoaminoxidase – eine nach wie vor zeitge-
mäße pharmakologische Zielstruktur der Depressi-
onsbehandlung mit Tranylcypromin
Manfred Gerlach, Germany
002
Von Fallberichten und kontrollierten Studien
zur Meta-Analyse – Tranylcypromin in der Therapie
der Depression
Roland Ricken, Germany
003
Klinische Pharmakologie und praktische
Therapie von Tranylcypromin: besondere Rolle bei
atypischer Depression?
Willem A. Nolen, The Netherlands
› Tuesday, 10 October 2017
InS-03
Industry Symposium
11:45– 13:15
|
Hall A5
Advances in schizophrenia: Why do we need new
treatment options?
Chair:
Christoph Correll, USA
Organisers:
Otsuka Pharmaceutical Development &
Commercialization, Inc & H. Lundbeck A/ S
001
Schizophrenia today and what we need tomorrow
Celso Arango, Spain
002
Pharmacology of the D2 partial agonists –
What they bring to the table
Leslie Citrome, USA
003
Brexpiprazole for treatment of patients with
acute schizophrenia – The short term perspective
John Kane, USA
004
Brexpiprazole for relapse prevention in
schizophrenia – The long term view
Christoph Correll, USA
005
Panel discussion
Christoph Correll, USA
InS-04
Industry Symposium
11:45– 13:15
|
Hall A4
Paving the way to remission from depression
Chairs:
Hans-Jürgen Möller, Germany
Siegfried Kasper, Austria
Organiser:
SERVIER
001
Meeting the challenge of characterizing
depressed patients' symptoms
Koen Demyttenaere, Belgium
002
Restoring functioning to achieve remission
Siegfried Kasper, Austria
003
Sharing our patients' experiences with agomel-
atine
Michael Landgrebe, Germany
004
Panel discussion
Hans-Jürgen Möller, Germany
Siegfried Kasper, Austria
› Wednesday, 11 October 2017
InS-05
Industry Symposium
11:45– 13:15
|
Room M8
Stimulieren, wenn Medikamente nicht mehr
helfen? Neurostimulation als Optionstherapie bei
schwerbehandelbaren Depressionen?
Chair:
Thomas E. Schläpfer, Germany
Organiser:
LivaNova Deutschland GmbH
001
Indikation zur VNS Therapy aus der Perspektive
des EKT-Anwenders
Here W. Folkerts, Germany
002
Vagusnervstimulation – klinische und theore-
tische Aspekte der psychiatrischen Anwendung
Helge Mueller, Germany
Industry Symposia